Lupin bags tentative USFDA approval for Rivaroxaban Tablets
This product will be manufactured at Lupin's Pithampur facility in India.;
Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg, to market a generic equivalent of Xarelto Tablets, 2.5 mg, 10 mg, 15 mg, and 20 mg, of Janssen Pharmaceuticals, Inc.
This product will be manufactured at Lupin’s Pithampur facility in India.
Rivaroxaban Tablets USP are indicated:
• to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation
• for treatment of deep vein thrombosis (DVT)
• for treatment of pulmonary embolism (PE)
• for reduction in the risk of recurrence of DVT or PE
• for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
• for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.